Impact of the number of repeated inhalations and patient characteristics on the residual amount of inhaled laninamivir octanoate hydrate dry powder in pediatric patients with influenza

Toshiki Murasaka1, Kenji Ikemura2, Tomoyuki Enokiya3, Yuichi Muraki3, Mayumi Ikemura1, Koji Terada4, Takuya Iwamoto2, Masahiro Okuda3
1Konan Pharmacy, Tsu, Mie, 514-0323, Japan
2Department of Clinical Pharmacy and Biopharmaceutics, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan
3Department of Pharmacy, Mie University Hospital, 2-174, Edobashi, Tsu, Mie, 514-8507, Japan
4Tsu Pharmaceutical Association, Tsu, Mie, 514-1135, Japan

Tóm tắt

Từ khóa


Tài liệu tham khảo

Ikematsu H, Kawai N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther. 2011;9:851–7.

Ikematsu H, Kawai N, Iwaki N, Kashiwagi S. Duration of fever and other symptoms after the inhalation of laminamivir octanoate hydrate for influenza treatment; comparison among the four Japanese influenza seasons from 2011 - 2012 to 2014 - 2015. J Infect Chemother. 2016;22:605–10.

Yoshida Y, Kawakubo T, Kaneyoshi Y, Sugihara Y. Investigation of inspiratory flow rate and post-administration residual volume of laninamivir. Gairai Syounika. 2013;16:148–53.

Okada M, Hara M, Hashida T, Okayama K, Morikawa K, Morikawa K, Shinada A, Matsushita R. Survey of the proper use of instructions and compliance for laminamivir octanoate dry powder inhalation in community pharmacies for treatment of influenza. J Jpn Primary Care Assoc. 2013;36:106–9.

Katsumi Y, Otabe O, Sakaue S, Tsuma Y, Yamaguchi M, Matsui F, Suematsu M, Miyagaki S, Ito H. Incomplete inhalation of laninamivir octanoate in children with influenza. Pediatr Ther. 2015;5:225.

Tabata Y, Arashiki Y. Examination of the number of inhalations required for children to inhale one blister of anti-influenza agent zanamivir. Jpn J Pediatr. 2010;63:463–5.

Kamps AW, Brand PL, Roorda RJ. Variation of peak inspiratory flow through dry powder inhalers in children with stable and unstable asthma. Pediatr Pulmonol. 2004;37:65–70.

Nielsen KG, Auk IL, Bojsen K, Ifversen M, Klug B, Bisgaard H. Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flowrates in asthmatic children. Eur Respir J. 1998;11:350–4.

Daiichi Sankyo Co., Ltd., Tokyo, Japan. General clinical evaluation: Dry powder inhaler of laninamivir octanoate. http://www.pmda.go.jp/drugs/2010/P201000050/430574000_22200AMX00925_G100_1.pdf . Accessed 26 May 2017.

Taylor TE, Holmes MS, Sulaiman I, Costello RW, Reilly RB. Influences of gender and anthropometric features on inspiratory inhaler acoustics and peak inspiratory flow rate. Conf Proc IEEE Eng Med Biol Soc. 2015;2015:2227–30.